Immix Biopharma Inc (IMMX)

$6.36 +0.15 (2.42%)
Market Cap 308.73M
Revenue (ttm) 0.00
Net Income (ttm) -21.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 937,200
Avg Vol 1,098,434
Day's Range N/A - N/A
Shares Out 52.96M
Stochastic %K 92%
Beta 0.31
Analysts Sell
Price Target $12.00

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 651 8041
Address:
11400 West Olympic Boulevard, Suite 200, Los Angeles, United States
WeTheNorth1234
WeTheNorth1234 Feb. 4 at 4:11 PM
$IMMX Recent data showed solid responses
0 · Reply
Monica69
Monica69 Feb. 4 at 3:47 PM
$IMMX Why? She gets momentum then Misfires. Stay long and strong. After all she is still up 230% for the last 12 months.
0 · Reply
WaltersWhite
WaltersWhite Feb. 4 at 7:26 AM
$IMMX
0 · Reply
DiamondHandsHarold
DiamondHandsHarold Feb. 3 at 10:40 PM
$IMMX has a real biotech story with actual progress behind it. Feels like one the market circles back to as the space heats up.
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 3 at 10:07 PM
$IMMX I’m really liking this X account!!! 21K followers and have given IMMX shout outs in two consecutive days https://x.com/bowtiedbiotech/status/2018750797467828382?s=46
0 · Reply
LuckyInvested
LuckyInvested Feb. 3 at 7:26 PM
$IMMX
0 · Reply
Daddy044
Daddy044 Feb. 3 at 6:57 PM
$IMMX much better data vs recent MAYO study
0 · Reply
Daddy044
Daddy044 Feb. 3 at 6:56 PM
$IMMX
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 3 at 6:24 PM
$IMMX enrollment update be like…
0 · Reply
jdkd4
jdkd4 Feb. 3 at 4:55 PM
$IMMX @jacksparo thank you for this wonderful stock pic Jack! I’m already up over $5000. It is incredible how closely this is following the plan you set out!
2 · Reply
Latest News on IMMX
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Jan 28, 2026, 8:45 AM EST - 7 days ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Dec 11, 2025, 12:10 AM EST - 7 weeks ago

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 5:45 PM EST - 2 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2025, 6:20 PM EST - 2 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Dec 7, 2025, 6:15 PM EST - 2 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 12, 2025, 8:45 AM EST - 3 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Nov 6, 2025, 2:39 PM EST - 3 months ago

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Nov 3, 2025, 8:45 AM EST - 3 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 8:45 AM EDT - 4 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Oct 6, 2025, 4:05 PM EDT - 4 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Oct 1, 2025, 8:45 AM EDT - 4 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Sep 18, 2025, 1:30 PM EDT - 4 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Sep 11, 2025, 9:15 AM EDT - 5 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Sep 8, 2025, 4:05 PM EDT - 5 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 25, 2025, 9:30 AM EDT - 5 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Immix Biopharma Announces Other Serious Diseases Strategy

Aug 6, 2025, 12:30 PM EDT - 6 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Jul 11, 2025, 9:36 AM EDT - 7 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jul 7, 2025, 9:35 AM EDT - 7 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Immix Biopharma Attends FDA CEO Forum in Washington DC

Jun 6, 2025, 9:39 AM EDT - 8 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Jun 3, 2025, 2:55 PM EDT - 8 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025, 9:05 AM EDT - 9 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025, 4:02 PM EDT - 9 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025, 4:03 PM EDT - 9 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Apr 23, 2025, 10:04 AM EDT - 10 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Feb 10, 2025, 9:35 AM EST - 1 year ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 20, 2024, 9:46 AM EDT - 2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Immix Biopharma 12 Month Review Progress Update

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 10:30 PM EST - 2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Proposed Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Jan 24, 2024, 8:35 AM EST - 2 years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dec 18, 2023, 9:39 AM EST - 2 years ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

WeTheNorth1234
WeTheNorth1234 Feb. 4 at 4:11 PM
$IMMX Recent data showed solid responses
0 · Reply
Monica69
Monica69 Feb. 4 at 3:47 PM
$IMMX Why? She gets momentum then Misfires. Stay long and strong. After all she is still up 230% for the last 12 months.
0 · Reply
WaltersWhite
WaltersWhite Feb. 4 at 7:26 AM
$IMMX
0 · Reply
DiamondHandsHarold
DiamondHandsHarold Feb. 3 at 10:40 PM
$IMMX has a real biotech story with actual progress behind it. Feels like one the market circles back to as the space heats up.
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 3 at 10:07 PM
$IMMX I’m really liking this X account!!! 21K followers and have given IMMX shout outs in two consecutive days https://x.com/bowtiedbiotech/status/2018750797467828382?s=46
0 · Reply
LuckyInvested
LuckyInvested Feb. 3 at 7:26 PM
$IMMX
0 · Reply
Daddy044
Daddy044 Feb. 3 at 6:57 PM
$IMMX much better data vs recent MAYO study
0 · Reply
Daddy044
Daddy044 Feb. 3 at 6:56 PM
$IMMX
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 3 at 6:24 PM
$IMMX enrollment update be like…
0 · Reply
jdkd4
jdkd4 Feb. 3 at 4:55 PM
$IMMX @jacksparo thank you for this wonderful stock pic Jack! I’m already up over $5000. It is incredible how closely this is following the plan you set out!
2 · Reply
Dingalingading
Dingalingading Feb. 3 at 4:01 PM
$IMMX
0 · Reply
Tester87100
Tester87100 Feb. 3 at 7:26 AM
$IMMX
0 · Reply
Mungermind
Mungermind Feb. 3 at 1:34 AM
$IMMX https://ashpublications.org/bloodadvances/article/10/3/535/547810/AL-amyloidosis-a-real-world-experience-with-CAR-T?searchresult=1 Mayo Clinic report outlining the results of using currently available commercial BCMA CarT (Abecma and Carvykti) for Al Amyloidosis. See the difference in response rates, CRS grade, and ICANS Their is a clear advantage in the safety and efficacy of NXC 201 for this disease (and perhaps other diseases?) Safety is critical when treating frail cancer patients (who can not tolerate severe toxicity risk) and in healthier autoimmune patients (who will not accept severe toxicity risk)
1 · Reply
KiingDrew
KiingDrew Feb. 2 at 9:22 PM
$IMMX Real progress, not just noise
0 · Reply
Wendysnow11
Wendysnow11 Feb. 2 at 7:26 PM
$IMMX
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 2 at 6:24 PM
$IMMX Interesting https://www.facebook.com/share/v/14YMSs6WxHr/?mibextid=wwXIfr
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 2 at 4:56 PM
$IMMX Great read
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 2 at 4:41 PM
$IMMX Wow!! https://x.com/bowtiedbiotech/status/2018271929069904383?s=46
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 4:07 PM
$IMMX RSI: 78.86, MACD: 0.2320 Vol: 0.56, MA20: 5.20, MA50: 5.27 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Tunes444
Tunes444 Feb. 2 at 2:45 PM
$IMMX We take a green start to the week
0 · Reply
CoralC
CoralC Feb. 2 at 7:26 AM
$IMMX
0 · Reply